Skip to contentB
BIO-TECHNE Corp
B
TECHBIO-TECHNE Corp Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$316.97M$316.97Mderived+3.5% vs Q4 2024 Net Income-$17.68M-$17.68MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BIO-TECHNE Corp · CIK 842023 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$198,813,000−2.2% Operating Incomederived-$23,859,000N/M Operating Cash Flowderived$98,201,000+30.1% Free Cash Flowderived$93,311,000+62.2% Margins · derivedGross margin62.7%−3.7 pt vs Q4 2024
Operating margin-7.5%−22.5 pt vs Q4 2024
Net margin-5.6%−18.8 pt vs Q4 2024
ended Jun 30, 2025 · filed Aug 22, 2025 · 53 d after period end